Cargando…

Novel Pyoverdine Inhibitors Mitigate Pseudomonas aeruginosa Pathogenesis

Pseudomonas aeruginosa is a clinically important pathogen that causes a variety of infections, including urinary, respiratory, and other soft-tissue infections, particularly in hospitalized patients with immune defects, cystic fibrosis, or significant burns. Antimicrobial resistance is a substantial...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirienko, Daniel R., Kang, Donghoon, Kirienko, Natalia V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333909/
https://www.ncbi.nlm.nih.gov/pubmed/30687293
http://dx.doi.org/10.3389/fmicb.2018.03317
_version_ 1783387640544886784
author Kirienko, Daniel R.
Kang, Donghoon
Kirienko, Natalia V.
author_facet Kirienko, Daniel R.
Kang, Donghoon
Kirienko, Natalia V.
author_sort Kirienko, Daniel R.
collection PubMed
description Pseudomonas aeruginosa is a clinically important pathogen that causes a variety of infections, including urinary, respiratory, and other soft-tissue infections, particularly in hospitalized patients with immune defects, cystic fibrosis, or significant burns. Antimicrobial resistance is a substantial problem in P. aeruginosa treatment due to the inherent insensitivity of the pathogen to a wide variety of antimicrobial drugs and its rapid acquisition of additional resistance mechanisms. One strategy to circumvent this problem is the use of anti-virulent compounds to disrupt pathogenesis without directly compromising bacterial growth. One of the principle regulatory mechanisms for P. aeruginosa’s virulence is the iron-scavenging siderophore pyoverdine, as it governs in-host acquisition of iron, promotes expression of multiple virulence factors, and is directly toxic. Some combination of these activities renders pyoverdine indispensable for pathogenesis in mammalian models. Here we report identification of a panel of novel small molecules that disrupt pyoverdine function. These molecules directly act on pyoverdine, rather than affecting its biosynthesis. The compounds reduce the pathogenic effect of pyoverdine and improve the survival of Caenorhabditis elegans when challenged with P. aeruginosa by disrupting only this single virulence factor. Finally, these compounds can synergize with conventional antimicrobials, forming a more effective treatment. These compounds may help to identify, or be modified to become, viable drug leads in their own right. Finally, they also serve as useful tool compounds to probe pyoverdine activity.
format Online
Article
Text
id pubmed-6333909
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63339092019-01-25 Novel Pyoverdine Inhibitors Mitigate Pseudomonas aeruginosa Pathogenesis Kirienko, Daniel R. Kang, Donghoon Kirienko, Natalia V. Front Microbiol Microbiology Pseudomonas aeruginosa is a clinically important pathogen that causes a variety of infections, including urinary, respiratory, and other soft-tissue infections, particularly in hospitalized patients with immune defects, cystic fibrosis, or significant burns. Antimicrobial resistance is a substantial problem in P. aeruginosa treatment due to the inherent insensitivity of the pathogen to a wide variety of antimicrobial drugs and its rapid acquisition of additional resistance mechanisms. One strategy to circumvent this problem is the use of anti-virulent compounds to disrupt pathogenesis without directly compromising bacterial growth. One of the principle regulatory mechanisms for P. aeruginosa’s virulence is the iron-scavenging siderophore pyoverdine, as it governs in-host acquisition of iron, promotes expression of multiple virulence factors, and is directly toxic. Some combination of these activities renders pyoverdine indispensable for pathogenesis in mammalian models. Here we report identification of a panel of novel small molecules that disrupt pyoverdine function. These molecules directly act on pyoverdine, rather than affecting its biosynthesis. The compounds reduce the pathogenic effect of pyoverdine and improve the survival of Caenorhabditis elegans when challenged with P. aeruginosa by disrupting only this single virulence factor. Finally, these compounds can synergize with conventional antimicrobials, forming a more effective treatment. These compounds may help to identify, or be modified to become, viable drug leads in their own right. Finally, they also serve as useful tool compounds to probe pyoverdine activity. Frontiers Media S.A. 2019-01-09 /pmc/articles/PMC6333909/ /pubmed/30687293 http://dx.doi.org/10.3389/fmicb.2018.03317 Text en Copyright © 2019 Kirienko, Kang and Kirienko. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Kirienko, Daniel R.
Kang, Donghoon
Kirienko, Natalia V.
Novel Pyoverdine Inhibitors Mitigate Pseudomonas aeruginosa Pathogenesis
title Novel Pyoverdine Inhibitors Mitigate Pseudomonas aeruginosa Pathogenesis
title_full Novel Pyoverdine Inhibitors Mitigate Pseudomonas aeruginosa Pathogenesis
title_fullStr Novel Pyoverdine Inhibitors Mitigate Pseudomonas aeruginosa Pathogenesis
title_full_unstemmed Novel Pyoverdine Inhibitors Mitigate Pseudomonas aeruginosa Pathogenesis
title_short Novel Pyoverdine Inhibitors Mitigate Pseudomonas aeruginosa Pathogenesis
title_sort novel pyoverdine inhibitors mitigate pseudomonas aeruginosa pathogenesis
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333909/
https://www.ncbi.nlm.nih.gov/pubmed/30687293
http://dx.doi.org/10.3389/fmicb.2018.03317
work_keys_str_mv AT kirienkodanielr novelpyoverdineinhibitorsmitigatepseudomonasaeruginosapathogenesis
AT kangdonghoon novelpyoverdineinhibitorsmitigatepseudomonasaeruginosapathogenesis
AT kirienkonataliav novelpyoverdineinhibitorsmitigatepseudomonasaeruginosapathogenesis